638 Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients With Ulcerative Colitis or Crohn's Disease
Brian Bressler(University of British Columbia), Gerassimos J. Mantzaris(European CanCer Organisation), Sumit Saha(Takeda (Canada)), Christina Kifnidi, Dirk Demuth(Takeda (Singapore)), Neil R. Brett(McGill University), Haridarshan Patel(Amgen (United States)), Uri Kopylov(Sheba Medical Center), Trevor Lissoos(Deerfield (United States)), Marielle Bassel, Athanasios Natsios(Municipality of Athens Development Agency), Claudia Lopez(Takeda (United States)), Andrés Yarur(Cedars-Sinai Medical Center)
Cited by 6
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
|Journal of Crohn s and Colitis|2019|1.1k
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
|Journal of Crohn s and Colitis|2021|1.1k